Triglav Investments D.O.O. Decreases Position in Thermo Fisher Scientific Inc. $TMO

Triglav Investments D.O.O. cut its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 30.0% during the fourth quarter, HoldingsChannel reports. The firm owned 15,814 shares of the medical research company’s stock after selling 6,781 shares during the quarter. Triglav Investments D.O.O.’s holdings in Thermo Fisher Scientific were worth $9,163,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Zhang Financial LLC raised its holdings in shares of Thermo Fisher Scientific by 17.1% in the fourth quarter. Zhang Financial LLC now owns 514 shares of the medical research company’s stock worth $298,000 after buying an additional 75 shares during the period. Fideuram Asset Management Ireland dac purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $6,662,000. Fiducient Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $423,000. Basepoint Wealth LLC purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $57,000. Finally, Northwestern Mutual Wealth Management Co. raised its holdings in shares of Thermo Fisher Scientific by 0.8% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 119,839 shares of the medical research company’s stock worth $69,442,000 after buying an additional 908 shares during the period. Institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on TMO. Stifel Nicolaus reduced their price target on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a report on Friday, April 24th. Wall Street Zen downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Barclays dropped their price objective on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 14th. Jefferies Financial Group raised Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $620.00 price objective on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $616.10.

Thermo Fisher Scientific Trading Up 1.1%

Shares of NYSE:TMO opened at $492.34 on Friday. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $643.99. The business’s fifty day simple moving average is $479.94 and its 200-day simple moving average is $534.64. The company has a market capitalization of $182.96 billion, a PE ratio of 27.07, a P/E/G ratio of 2.16 and a beta of 0.88. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the firm earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities research analysts predict that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be given a $0.47 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.34%.

Insiders Place Their Bets

In other news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $63,499,170. The trade was a 3.88% decrease in their position. The SEC filing for this sale provides additional information. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.